✦ LIBER ✦

Second-Line Therapy for Patients With Chronic Myeloid Leukemia Resistant to First-Line Imatinib

✍ Scribed by Lau, Anna; Seiter, Karen

Book ID: 122664494
Publisher: Elsevier
Year: 2014
Tongue: English
Weight: 337 KB
Volume: 14
Category: Article
ISSN: 2152-2650
DOI: 10.1016/j.clml.2013.11.002

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Optimizing First-Line Therapy for Patien

Optimizing First-Line Therapy for Patients With Chronic Myeloid Leukemia

✍ Carmen Fava; Jorge Cortes 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 436 KB

Second-line Therapy and Beyond Resistanc

Second-line Therapy and Beyond Resistance for the Treatment of Patients With Chronic Myeloid Leukemia Post Imatinib Failure

✍ Jabbour, Elias; Cortés, Jorge E.; Kantarjian, Hagop 📂 Article 📅 2009 🏛 CIG Media Group, LP. 🌐 English ⚖ 174 KB

First-line treatment for chronic myeloid

First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib

✍ Guoqing Wei; Shamudheen Rafiyath; Delong Liu 📂 Article 📅 2010 🏛 BioMed Central 🌐 English ⚖ 298 KB

Nilotinib is superior to imatinib as fir

Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: the ENESTnd study

✍ Giles, Francis J; Rosti, Gianantonio; Beris, Photis; Clark, Richard E; le Coutre 📂 Article 📅 2010 🏛 Expert Reviews 🌐 English ⚖ 731 KB

Philadelphia-negative acute myeloid leuk

Philadelphia-negative acute myeloid leukemia with new chromosomal abnormalities developing after first-line imatinib treatment for chronic phase chronic myeloid leukemia

✍ Carmen Fava; Jorge Cortes 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 306 KB 👁 2 views

## Induction of integrin b 1 expression in bone marrow cells after chemotherapy correlates with the overexpression of lung resistance protein and poor outcome in patients with multiple myeloma To the Editor: Acquired drug resistance continues to be one of the major obstacles hindering the successf

Adherence to treatment with second-line

Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia

✍ Yood, Marianne Ulcickas; Oliveria, Susan A.; Cziraky, Mark; Hirji, Ishan; Hamdan 📂 Article 📅 2012 🏛 Informa plc 🌐 English ⚖ 206 KB